Steroids ( DrugBank: - )
7 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 3 |
50 | Dermatomyositis | 2 |
51 | Scleroderma | 1 |
63 | Idiopathic thrombocytopenic purpura | 1 |
66 | IgA nephropathy | 9 |
96 | Crohn disease | 6 |
97 | Ulcerative colitis | 3 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03852355 (ClinicalTrials.gov) | February 25, 2019 | 22/2/2019 | the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis | the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis; a Randomized Controlled Trial | Rheumatoid Arthritis;Headache | Drug: Radiofrequency;Drug: Steroids | Assiut University | NULL | Completed | 18 Years | 60 Years | All | 60 | N/A | Egypt |
2 | NCT01287533 (ClinicalTrials.gov) | April 2010 | 30/1/2011 | Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids | Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids | Rheumatoid Arthritis;Osteoporosis;Osteopenia | Drug: Ibandronate;Drug: Placebo | Yeong-Wook Song | NULL | Completed | 18 Years | 75 Years | Female | 167 | Phase 4 | Korea, Republic of |
3 | NCT00233558 (ClinicalTrials.gov) | June 2005 | 13/9/2005 | Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis | Multicentre, Randomised, Open Label Study Comparing a Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months | Rheumatoid Arthritis | Drug: adalimumab (up to 9 months exposure);Drug: methotrexate | Abbott | NULL | Terminated | 18 Years | N/A | Both | 160 | Phase 4 | United States |
50. Dermatomyositis
Clinical trials : 182 / Drugs : 229 - (DrugBank : 88) / Drug target genes : 48 - Drug target pathways : 147
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03192657 (ClinicalTrials.gov) | July 2017 | 15/6/2017 | Basiliximab Treating Interstitial Pneumonia of CADM | Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients | Lung; Disease, Interstitial, With Fibrosis;Dermatomyositis | Drug: Basiliximab;Drug: Calcineurin Inhibitors;Drug: Steroids | RenJi Hospital | NULL | Not yet recruiting | 18 Years | 65 Years | All | 100 | Phase 2 | China |
2 | EUCTR2005-003129-23-GB (EUCTR) | 18/04/2006 | 24/02/2006 | To prevent and treat osteoporosis in children with rhuematic diseases taking steroids | Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases - POPS | Children and adolescents with Juvenile Idiopathic arthritis (JIA), Juvenile dermatomyositis (JDMS) Juvenile systemic lupus erythematosis (JSLE) Vasculitis;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Risedronate Sodium Product Code: 35mg Other descriptive name: RISEDRONATE SODIUM Product Name: Risedronate Sodium Product Code: 5mg Other descriptive name: RISEDRONATE SODIUM Trade Name: One-Alpha drops Product Name: One Alpha Drops Product Code: alfacalcidol 2 micrograms/ml INN or Proposed INN: ALFACALCIDOL Other descriptive name: drops | Belfast Health and Social Care Trust, Musgrave Park Hospital | NULL | Not Recruiting | Female: yes Male: yes | 216 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |
51. Scleroderma
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03068234 (ClinicalTrials.gov) | May 2017 | 16/2/2017 | Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis | A Randomized, Double-blinded, Placebo Controlled Study to Evaluate Clinical Efficacy and Safety of Pirfenidone for Skin Fibrosis in Systemic Sclerosis | Systemic Sclerosis | Drug: Pirfenidone;Drug: Placebo oral capsule;Drug: Steroids | RenJi Hospital | NULL | Not yet recruiting | 18 Years | 70 Years | All | 72 | Phase 2/Phase 3 | China |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 363 / Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04113915 (ClinicalTrials.gov) | November 2019 | 1/10/2019 | Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy | Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy | ITP - Immune Thrombocytopenic Purpura;Viral Hepatitis | Drug: triple therapy;Drug: Steroids | Safaa AA Khaled | NULL | Not yet recruiting | 18 Years | 75 Years | All | 150 | NULL |
66. IgA nephropathy
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04833374 (ClinicalTrials.gov) | May 24, 2021 | 4/4/2021 | Steroids Therapy in IgA Nephropathy With Crescents | Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. | IgA Nephropathy | Drug: Methylprednisolone | Sixth Affiliated Hospital, Sun Yat-sen University | NULL | Recruiting | 14 Years | 65 Years | All | 200 | Phase 3 | China |
2 | NCT02160132 (ClinicalTrials.gov) | June 2014 | 3/6/2014 | A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. | Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. | Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid Nephropathy | Drug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intravenously in the 1st-3rd-5th month) | Sun Yat-sen University | NULL | Recruiting | 14 Years | 65 Years | Both | 180 | Phase 2 | China |
3 | NCT01560052 (ClinicalTrials.gov) | May 5, 2012 | 15/3/2012 | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study | IgA Glomerulonephritis | Drug: methylprednisolone;Drug: Placebo | The George Institute | Peking University First Hospital | Completed | 18 Years | N/A | All | 503 | N/A | Australia;Canada;China;Hong Kong;India;Malaysia |
4 | NCT01451710 (ClinicalTrials.gov) | March 2011 | 7/10/2011 | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | IgA Nephropathy | Drug: Prednisone or Prednisolone | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 30 | N/A | China |
5 | ChiCTR-TRC-09000338 | 2009-04-01 | 2009-02-23 | Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy | Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy | IgA nephropathy | Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ; | The First Affiliated Hospital of Zhejiang University | NULL | Completed | 18 | 70 | Male | Group A:60;Group B:60; | China | |
6 | ChiCTR-TRC-06000004 | 2006-01-01 | 2006-09-14 | ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial | ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial | primary IgA nephropathy | group 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB; | The First Hospital, Peking University | NULL | Completed | 16 | 65 | Both | group 1:78;group 2:78; | China | |
7 | NCT00378443 (ClinicalTrials.gov) | January 2006 | 19/9/2006 | ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT | Glomerulonephritis, IGA | Drug: prednisone + Inhibace/Cozaar;Drug: Inhibace/Cozaar | Peking University | NULL | Active, not recruiting | 16 Years | 65 Years | Both | N/A | NULL | ||
8 | NCT01392833 (ClinicalTrials.gov) | December 1999 | 5/7/2011 | Steroids and Azathioprine in Advanced IgAN | Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial | IgA Nephropathy;Chronic Kidney Disease | Drug: methylprednisolone;Drug: azathioprine;Drug: prednisone | A. Manzoni Hospital | NULL | Completed | 16 Years | 70 Years | Both | 46 | Phase 3 | NULL |
9 | NCT00755859 (ClinicalTrials.gov) | May 1998 | 18/9/2008 | Steroids and Azathioprine Versus Steroids Alone in IgAN | Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. | IGA Nephropathy | Drug: steroids plus azathioprine;Drug: steroids | A. Manzoni Hospital | NULL | Completed | 16 Years | 70 Years | Both | 206 | Phase 4 | Italy;Switzerland |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2014-002311-41-SE (EUCTR) | 21/08/2015 | 01/07/2015 | A prospective randomized controlled study comparing continuing treatment with an anti-TNF antibody (infliximab) and an antimetabolite to contiuing with a single agent, either with the anti-TNF antibody or the anti-metabolite in Crohn’s disease in patients without clinical sympthoms and without steroids on combination therapy | A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy | Crohn´s disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Imurel 25 mg Product Name: Imurel INN or Proposed INN: AZATHIOPRINE Other descriptive name: AZATHIOPRINE Trade Name: Puri-Nethol 50 mg Product Name: Puri-Nethol INN or Proposed INN: MERCAPTOPURINE Trade Name: Metoject Product Name: Metotrexat INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE DISODIUM Trade Name: Remsima Product Name: Remsima INN or Proposed INN: INFLIXIMAB | GETAID | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 225 | Phase 4 | France;Netherlands;Germany;United Kingdom;Sweden | ||
2 | NCT02619552 (ClinicalTrials.gov) | August 2011 | 28/10/2015 | Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease | Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease | Crohn's Disease;IBD | Drug: Anti-TNF;Drug: Steroids | University of Maryland, Baltimore | Vanderbilt University;Milton S. Hershey Medical Center;Mercy Medical Center | Completed | 18 Years | N/A | All | 50 | United States | |
3 | EUCTR2006-006632-22-BE (EUCTR) | 26/01/2007 | 19/12/2006 | Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. - Infliximab to adalimumab switch trial | Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. - Infliximab to adalimumab switch trial | Luminal Crohns Disease, moderate to severe, refractory to steroids and/or antimetabolitets and controlled with anti-TNF therapy MedDRA version: 8.1;Level: LLT;Classification code 10011401;Term: Crohn's disease | Trade Name: HUMIRA Trade Name: REMICADE | University of Leuven, Division of Gastroenterology | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 4 | Belgium | ||
4 | NCT00294112 (ClinicalTrials.gov) | March 13, 2006 | 17/2/2006 | Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease | A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants | Crohn's Disease | Drug: Prochymal™ adult human mesenchymal stem cells;Drug: adult human mesenchymal stem cells | Mesoblast, Inc. | NULL | Completed | 18 Years | 70 Years | All | 10 | Phase 2 | United States |
5 | NCT00265772 (ClinicalTrials.gov) | November 2005 | 14/12/2005 | Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis | Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis | Crohn's Disease;Pediatric | Drug: MODULEN IBD (R) (specific Enteral Nutrition);Drug: prednisolon | Hôpital Necker-Enfants Malades | Institut National de la Santé Et de la Recherche Médicale, France;Nestlé | Recruiting | 6 Years | 18 Years | Both | 24 | Phase 4 | France |
6 | NCT00206596 (ClinicalTrials.gov) | July 2003 | 12/9/2005 | Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease | Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim (Leukine) Therapy in Patients With Cortico-Dependent Crohn's Disease | Crohn Disease | Drug: Sargramostim (Leukine);Drug: Placebo | Genzyme, a Sanofi Company | NULL | Completed | 18 Years | 80 Years | Both | 127 | Phase 2 | United States;Canada |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03460847 (ClinicalTrials.gov) | March 1, 2018 | 22/2/2018 | Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa | Can Fecal Microbiota Alterations Predict a Refractory Disease Course to Standard Steroid Therapy in Patients With Active Ulcerative Colitis? | Colitis, Ulcerative | Drug: Steroids | Medical University of Graz | NULL | Completed | 18 Years | N/A | All | 114 | Austria | |
2 | NCT02425852 (ClinicalTrials.gov) | December 2016 | 21/4/2015 | A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis | A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis | Ulcerative Colitis | Drug: Azathioprine;Drug: Infliximab;Drug: Prednisolone;Drug: Hydrocortisone | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | NULL | Recruiting | 18 Years | N/A | All | 146 | Phase 4 | France |
3 | ChiCTR-ICR-15007188 | 2015-10-09 | 2015-10-09 | Percutaneous endoscopic mini-colostomy anddrug delivery system for the treatment of ulcerative colitis: A randomized, controlled clinical trial | Percutaneous endoscopic mini-colostomy anddrug delivery system for the treatment of ulcerative colitis: A randomized, controlled clinical trial | Ulcerative colitis | Percutaneous endoscopic mini-colostomy group:Oral steroids (prednisone 1mg.kg-1d-1) +Percutaneous endoscopic mini-colostomy andsubsequent drug delivery (mesalazine 3g / d);Control Group:Oral steroids (prednisone 1mg.kg-1d-1) andmesalazine 3g / d; | Southern Medical University, Nanfang Hospital, Department of Gastroenterology | NULL | Recruiting | Both | Percutaneous endoscopic mini-colostomy group:21;Control Group:21; | China |